Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph early_phase_1
2
40%
Ph phase_3
1
20%
Ph phase_1
1
20%
Ph phase_4
1
20%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
2(40.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Suspended1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (40.0%)
Phase 11 (20.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

completed240%
suspended120%
withdrawn120%
terminated120%

Recent Activity

Clinical Trials (5)

Drug Details

Intervention Type
OTHER
Total Trials
5